Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst

Key Points

• Brookline Capital Markets lowered its Q3 2026 EPS forecast for Kymera Therapeutics to a loss of $1.31 per share from $1.11, while maintaining a “Buy” rating. The analyst projects full-year 2026 and 2027 losses of $3.97 and $5.28 per share, respectively.
• Kymera’s second-quarter results beat expectations, with a $0.62 per-share loss versus the projected $0.71 loss and revenue of $65 million versus $32.78 million expected. Revenue surged 465% year over year, helped by milestone payments from Gilead Sciences and Sanofi.
• The company has approximately $1.5 billion in cash and expects funding to last into 2029, while clinical catalysts include KT-621 atopic dermatitis data by year-end 2026. However, Kymera remains unprofitable, and insiders have sold roughly $387.8 million of stock over the past 90 days.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Brookline Capital Markets cut their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a report released on Wednesday, August 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of ($1.31) per share for the quarter, down from their previous forecast of ($1.11). Brookline Capital Markets currently has a "Buy" rating on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.29) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.33) EPS, FY2026 earnings at ($3.97) EPS, FY2027 earnings at ($5.28) EPS, FY2028 earnings at ($6.18) EPS and FY2029 earnings at ($5.61) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.82%. The company had revenue of $65.00 million for the quarter, compared to analysts' expectations of $32.78 million. During the same period in the prior year, the firm earned ($0.95) EPS. Kymera Therapeutics's quarterly revenue was up 465.2% compared to the same quarter last year.

Several other analysts have also issued reports on the company. Mizuho upped their price objective on Kymera Therapeutics from $120.00 to $140.00 and gave the company an "outperform" rating in a research note on Thursday, July 16th. B. Riley Financial boosted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Wall Street Zen upgraded Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $135.00 price objective on shares of Kymera Therapeutics in a research report on Thursday. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $125.65.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $106.41 on Friday. The stock has a 50-day simple moving average of $100.79 and a 200 day simple moving average of $88.66. The stock has a market capitalization of $8.75 billion, a P/E ratio of -32.84 and a beta of 1.95. Kymera Therapeutics has a 52 week low of $36.65 and a 52 week high of $130.05.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the completion of the sale, the director owned 461,794 shares of the company's stock, valued at $50,557,207.12. The trade was a 6.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares of the company's stock, valued at approximately $79,321,592. The trade was a 6.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 3,607,813 shares of company stock worth $387,818,004. 15.98% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP lifted its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC increased its stake in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. raised its position in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Commodore Capital LP bought a new stake in Kymera Therapeutics during the second quarter worth $32,730,000.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported a second-quarter loss of $0.62 per share, narrower than the consensus estimate of a $0.71 loss and improved from a $0.95 loss a year earlier. Revenue reached $65.0 million versus analyst expectations of $32.78 million, representing 465% year-over-year growth. KYMR Q2 results
• Positive Sentiment: Revenue was boosted by milestone payments from partners Gilead Sciences and Sanofi, while the company continues advancing KT-621, its STAT6 degrader. The payments and better cost performance provide near-term financial support. Q2 earnings and revenue beat
• Positive Sentiment: Enrollment in the BROADEN2 Phase 2b trial of KT-621 in atopic dermatitis finished nearly six months ahead of schedule. Kymera expects topline data by year-end 2026, a potentially important catalyst for the stock, and plans to begin Phase 3 studies by mid-2027. Second-quarter results and business update
• Positive Sentiment: Kymera ended June with approximately $1.5 billion in cash and expects its runway to extend into 2029, reducing near-term financing and dilution risk while it develops KT-621, KT-579 and partnered KT-485.
• Neutral Sentiment: Additional catalysts include KT-579 Phase 1 data expected in the fourth quarter of 2026 and KT-621 asthma data anticipated in late 2027. However, the investment case remains dependent on clinical efficacy and safety results that have not yet been reported. KT-621 data and cash runway
• Negative Sentiment: Although the quarterly loss narrowed, Kymera remains unprofitable, and a substantial portion of the revenue beat came from milestone payments that may not recur each quarter. The company is still forecast to post a full-year loss.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source